VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DHRDanaher Corporation
$225.77$158.7B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDHRCash Flow

Danaher Corporation (DHR) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow exceeded net income in every reported quarter (OCF/NI as high as 2.41x) and FCF margin recovered to 24.9% in 2026Q3, though capex at 3.9% of revenue runs roughly half of the ~$600M quarterly D&A.

Income StatementBalance SheetCash FlowRatios

DHR Cash Flow Statement

Annual statement

DHR Cash Flow Statement

Danaher Corporation (DHR) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations6.86B6.42B6.69B7.16B8.52B8.36B6.21B3.95B4.02B3.48B3.52B3.8B3.76B3.59B3.42B2.63B2.08B1.8B1.86B1.65B1.55B1.2B1.03B861.54M710.35M608.47M512.25M419.1M331.3M278.4M217.1M
Operating CF Margin %-26.12%28.01%29.99%31.97%28.38%27.86%22.06%23.59%18.97%20.86%26.34%18.87%18.75%18.7%16.32%15.79%16.1%14.64%14.93%16.12%15.08%15%16.27%15.52%16.09%13.56%13.11%11.38%13.57%11.98%
Operating CF Growth %34.75%-4.07%-6.64%-15.91%1.93%34.63%57.1%-1.75%15.65%-1.25%-7.36%1.15%4.83%4.99%30.03%26%15.74%-3.13%12.96%6.37%28.53%16.51%19.93%21.28%16.74%18.79%22.23%26.5%19%28.24%24.63%
Net Income4.33B3.61B3.9B4.22B7.21B6.35B3.65B2.43B2.65B2.47B2.15B2.6B2.6B2.69B2.3B1.94B1.79B1.15B1.32B1.37B1.12B897.8M746M536.83M290.39M297.67M324.21M261.6M182.9M154.8M207.8M
Depreciation & Amortization1.91B2.45B2.35B2.17B2.13B2.17B1.77B1.19B1.18B1.24B1.13B1.05B938.5M895M839.8M634.93M397.08M341.59M339.29M268.49M217.19M176.97M156.13M133.44M129.56M178.39M149.72M126.4M108.7M76.1M68.6M
Stock-Based Compensation297M298M288M306M295M184M187M158.8M151.4M139.4M129.8M139M121.1M117.7M109.9M95.6M88.12M87.35M86M000000000000
Deferred Taxes-440M-440M00-559M-318M-462M-415.2M-195.1M-426.9M-383.9M-151.3M177.3M254.6M184.9M271.39B00-27.69M29.87M24.15M0000000000
Other Non-Cash Items991M1.21B-117M864M961M601M457M709.4M326.9M410.2M773.6M112.7M-333.8M-619.3M-297.4M-271.52B-313.81M-84.75M27.69M-136.09M67.19M000143.75M00037.4M59.4M-96.8M
Working Capital Changes-229M-710M266M-393M-1.52B-658M605M-123.2M-90.1M-353M-279.2M51.4M256.9M242.3M278.5M84.63M119.95M304.94M116.11M113.6M116.69M129.03M131.09M191.27M146.64M132.42M38.31M31.1M2.3M-11.9M37.5M
Change in Receivables-174M-216M331M322M-477M-611M-264M-156.4M-58.3M-161.4M-183.1M-52.1M-142.2M-48.7M-79.7M-135.28M-262.12M106.13M71.4M0000059.03M000000
Change in Inventory-45M-58M147M185M-486M-502M-123M-21.9M-143.3M-27.4M9.4M119.7M50.6M62.9M69.8M162.02M-166.45M211.59M33.12M38.09M3.37M-22.48M65.53M21.06M77.54M66.83M-38.45M11.1M12.5M14.7M38.9M
Change in Payables-17M9M19M-149M5M549M227M18.1M225.8M-54.4M78.1M103.9M118.4M182.6M57M36.6M224.71M-89.85M3.71M0000054.01M000000
Cash from Investing-11.08B-1.2B-1.98B-7.08B-2.23B-12.99B-21.24B-1.24B-2.95B-843.4M-5.24B-14.95B-3.44B-552.5M-1.89B-5.85B-2.29B-942.94M-567.4M-3.45B-2.77B-965.41M-1.63B-368.05M-1.14B-487.57M-795.3M-153.7M-599.7M-210M-142.7M
Capital Expenditures-1.13B-1.16B-1.39B-1.38B-1.15B-1.29B-791M-635.5M-584M-570.7M-589.6M-512.9M-465.4M-538.1M-458.3M-334.47M-217.33M-188.55M-193.78M-162.07M-137.71M-121.21M-115.91M-80.34M-65.43M-80.58M-88.5M-153.7M-616M-62.8M-51.3M
CapEx % of Revenue4.42%4.71%5.83%5.79%4.32%4.39%3.55%3.55%3.43%3.11%3.49%3.55%2.34%2.81%2.51%2.08%1.65%1.69%1.53%1.47%1.44%1.52%1.68%1.52%1.43%2.13%2.34%4.81%21.17%3.06%2.83%
Acquisitions-9.84B9M-558M-5.61B-637M-10.94B-20.14B-331.3M-2.17B-385.8M-4.88B-14.3B-3.13B-249.8M-1.8B-6.2B-2.07B-703.51M-423.21M-3.58B-2.66B-885.08M-1.59B-312.28M-1.16B-406.99M-706.79M0000
Investments-------------------------------
Other Investing-191M66M47M23M60M50M26M28.9M-65M-272.7M-4.65B-89M-2.98B-14.4M367.5M683.28M1.56M15.88M1.09M14.81M-74.11M40.88M30.89M24.57M79.03M00016.3M-147.2M-91.4M
Cash from Financing8.32B-2.96B-8.38B-273M-2.57B1.29B1.01B16.37B-797M-3.1B2.04B9.05B-218.2M-1.61B-388.4M2.09B116.8M407.23M-1.12B1.71B1.22B-511.56M-38.05M-110.34M516.3M409.71M200.48M-51.8M238.3M-61.3M-56.1M
Debt Issued (Net)8.31B1.04B-1.67B-1.63B-1.69B1.97B-1.9B13.35B-442M-2.66B2.79B9.16B-414.7M-967.8M134.4M1.04B-9.4M274.72M-1.09B1.13B1.15B-292.24M-66.28M-145.51M17.71M410.52M266.09M-129.9M214.9M-10.8M-55.4M
Equity Issued (Net)-930M-3B-5.82B68M31M86M3.55B3.82B96M68.8M164.5M249M0177.4M-436.4M1.11B178.4M174.23M8.27M615.54M98.42M-197.76M45.96M50.5M512.11M10.87M-55.59M87.9M28.4M-71.1M-3.2M
Dividends Paid-1.02B-878M-768M-821M-818M-742M-615M-526.7M-433.4M-378.3M-399.8M-354.1M-227.7M-52.1M-86.4M-61.32M-52.21M-41.72M-38.26M-34.27M-24.59M-21.55M-17.73M-15.33M-13.52M-11.68M-10.02M-9.9M-10.5M-5.9M-5.1M
Share Repurchases-919M-3.09B-5.98B00000000000-648.4M000-74.17M-117.49M0-257.7M000-17.3M-82.17M0-2.1M-80.2M-12.1M
Other Financing1.96B-125M-131M2.11B-95M-16M-29M-274.7M-17.6M-124.2M-512.3M-3.3M424.2M-763.3M02.09T0000000-15.33M000100K7.8M-8.7M-6.1M
Net Change in Cash4.16B2.54B-3.79B-131M3.41B-3.45B-13.88B19.12B157.7M-333.4M172.9M-2.21B-109.6M1.44B1.14B-1.1B-88.94M1.33B153.75M-78.7M2.26M-293.56M-621.04M419.69M103.9M529.63M-83.36M212.5M-28.9M6.9M18.4M
Free Cash Flow5.73B5.26B5.3B5.78B7.37B7.06B5.42B3.32B3.44B2.91B2.93B3.29B3.29B3.05B2.96B2.29B1.87B1.61B1.67B1.48B1.41B1.08B917.31M781.2M644.92M527.89M423.74M265.4M-284.7M215.6M165.8M
FCF Margin %22.36%21.41%22.18%24.2%27.65%23.98%24.31%18.51%20.17%15.86%17.37%22.79%16.54%15.94%16.19%14.24%14.14%14.41%13.11%13.46%14.69%13.56%13.31%14.76%14.09%13.96%11.22%8.3%-9.78%10.51%9.15%
FCF Growth %14.15%-0.68%-8.39%-21.53%4.29%30.4%63.35%-3.55%18.26%-0.86%-10.85%-0.12%8.07%3.06%29.01%22.75%15.8%-3.18%12.24%5.26%30.2%18.02%17.42%21.13%22.17%24.58%59.66%193.22%-232.05%30.04%44.17%
FCF per Share8.107.407.187.789.999.597.544.574.844.124.194.644.604.294.153.272.732.402.482.252.171.651.401.211.020.870.730.45-0.490.370.30
FCF Conversion (FCF/Net Income)1.32x1.78x1.72x1.50x1.18x1.30x1.70x1.55x1.52x1.40x1.38x1.46x1.45x1.33x1.49x1.33x1.16x1.56x1.41x1.35x1.38x1.34x1.39x1.60x2.45x2.04x1.58x1.60x1.81x1.80x1.04x
Interest Paid-95M331M370M0347M00000000000000000000000000
Taxes Paid-267M000000000000000000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowRobust
Top Statement Risk

Acquisition outflows outpacing FCF

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Consistently Convert to Cash

Operating cash flow exceeded net income in all ten reported quarters, with the OCF/NI ratio ranging from 1.28x to 2.41x; cumulatively, Danaher generated roughly $16.0B of operating cash against approximately $9.5B of GAAP net income, per its quarterly filings.

The persistent gap is largely structural rather than opportunistic: quarterly depreciation and amortization held steady between $580M and $659M, dwarfing the $57M-$146M of stock-based compensation, so non-cash add-backs alone plausibly explain most of the delta. This suggests reported earnings are a conservative proxy for economic performance, though the 2.41x print in 2025Q2 — a quarter where net income troughed at $555M — shows the ratio can be mechanically inflated when the denominator is depressed by non-operating charges, so the trend matters more than any single quarter.

Free Cash Flow Margins Reaccelerate

Danaher's free cash flow margin recovered from an 18.2% trough in 2026Q1 to 24.9% in 2026Q3, generating approximately $1.6B of FCF in the latest quarter and cumulatively about $13.1B over the ten-quarter window on a reported basis.

The trajectory mirrors the income statement's post-destocking recovery: FCF margins of 18.4% in both 2025Q1 and 2025Q2 gave way to 22.6%-25.5% in the second half of 2025 before a Q1 seasonal dip, indicating the bioprocessing inventory rebalancing weighed on cash generation as well as revenue. At 24.9%, Danaher's current FCF margin sits materially above Thermo Fisher's 16.0% and Agilent's 19.5%, which may support the premium multiple, but investors should note the latest print also benefited from a $306M working capital draw that may not repeat.

Capital Intensity Falls Below Depreciation

Capital expenditure as a share of revenue declined from 7.9% in 2024Q4 to 3.9% in 2026Q3, while quarterly depreciation and amortization of roughly $600M ran about 2x capex, implying the company is currently spending well below asset replacement levels.

A capex-to-D&A ratio persistently below 1.0x ($237M-$371M of quarterly capex against $580M-$659M of D&A) reads as a genuinely asset-light consumables model, but it also raises the question of whether growth investment is being deferred amid weak biotech funding. The elevated 7.9% ratio in 2024Q4 likely reflects a one-time build-out rather than a structural shift, and if the recent 3.9%-4.3% range persists while revenue accelerates, operating leverage should improve — unless it signals underinvestment that surfaces as capacity constraints later.

Acquisitions Absorb Multiple Years of FCF

Danaher deployed approximately $9.8B net toward acquisitions in 2026Q2 and $4.5B in 2024Q2, alongside roughly $10.0B of cumulative buybacks and steadily rising dividends from $194M to $281M per quarter, per cash flow statement disclosures.

The pattern shows a clear hierarchy: dividends are the only consistently growing commitment, while buybacks are lumpy and strategically scaled back (from $4.5B in 2024Q2 to zero in the last three quarters) to fund M&A. A single quarter's $9.8B acquisition outflow exceeded two full years of that period's cumulative free cash flow, which implies either meaningful incremental borrowing or a substantial draw on the cash balance — either way, the balance sheet absorbed a step-change in 2026Q2 that warrants monitoring for leverage normalization.

What the Cash Flow Statement Obscures

Reported FCF of $1.6B in 2026Q3 excludes the full cash cost of stock-based compensation, which ran $57M-$146M in prior quarters, and the period's working capital release of $306M, meaning underlying discretionary cash generation was likely closer to $1.2B-$1.3B.

Additionally, the zero values shown for SBC and depreciation in 2026Q3 and the blank acquisition line should be treated as data unavailable rather than as genuine zeros, so the latest quarter's quality of cash cannot be fully reconciled from this dataset. More broadly, FCF as presented does not capture the deferred maintenance implied by capex at roughly half of D&A, nor the integration cash costs associated with the Abcam purchase; investors should also weigh that the bioprocessing destocking tailwind now reversing may have temporarily flattered receivables, making the recent conversion advantage less durable than the headline ratios suggest.

DHR — Frequently Asked Questions

Quick answers to the most common questions about buying DHR stock.

How much cash does Danaher Corporation (DHR) generate from operations?

Danaher Corporation (DHR) generated $6.42B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Danaher Corporation's free cash flow?

Danaher Corporation (DHR) generated $5.26B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Danaher Corporation's capital expenditure (CapEx)?

Danaher Corporation (DHR) spent $1.16B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Danaher Corporation distribute cash to shareholders?

In 2025, Danaher Corporation (DHR) returned $878.0M to shareholders via cash dividends and spent $3.09B on share repurchases. This shows the company's commitment to returning capital to its equity investors.